A study found that treatment with Paxlovid significantly reduced the duration and severity of SARS-CoV-2 infection among high-risk patients, resulting in fewer hospitalizations, ICU admissions, and deaths. The study included unvaccinated, high-risk adult patients with symptomatic COVID-19 who were randomized to receive either Paxlovid or a placebo every 12 hours for 5 days. Patients who received Paxlovid had shorter hospital stays, fewer medical visits, and a lower mortality rate compared to those who received the placebo. These findings suggest that Paxlovid may reduce the burden of COVID-19 on healthcare systems during future waves of infection.
Source link
Study provides more positive data for Paxlovid use in high-risk patients with COVID-19
